NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
Novavax (NASDAQ: NVAX) stock has plunged in recent weeks despite the company reporting several positive developments for its COVID-19 vaccine. In this Motley Fool Live video recorded on Jan. 5, Fool contributors Keith Speights and Brian Orelli discuss what it might take for Novavax to rebound. Novavax has won European authorization for its COVID-19 vaccine.
New York, NY, based Investment company Edge Wealth Management LLC (Current Portfolio) buys SPDR Biotech ETF, Salesforce.com Inc, Invesco BulletShares 2024 Corporate Bond ETF, Invesco Senior Loan ETF, iShares J.P.
Novavax (NASDAQ:NVAX), the Gaithersburg, Maryland-based biotech company, still has not submitted its Covid-19 vaccine for emergency use approval (EUA) to the Food and Drug Administration (FDA). The company says it will do so by the end of January. But the market is skeptical and is still waiting to see when the EUA will happen. As a result, NVAX stock has been treading water. Source: vovidzha / Shutterstock.com For example, Novavax stock reached a near-term peak of $270.58 on Sept. 7, but it has
Novavax stock and shares of other vaccine makers fell Friday after the Supreme Court blocked the Biden administration’s vaccine mandate for companies that employ 100 workers or more. The Supreme Court’s conservative majority dealt a major setback to the Biden administration’s effort to boost vaccination rates on Thursday, ruling that the government didn’t have the unilateral power to impose the mandate for all large businesses through the Occupational Safety and Health Administration. “These SCOTUS decisions are in alignment with what we expected,” wrote Raymond James analyst Chris Meekins in a research note.
As markets opened today, the vaccine industry is faced with a bleak landscape. Yesterday, the U.S. Supreme Court (USSC) blocked the vaccine mandate proposed by President Joe Biden’s administration. With the policy that would have required vaccinations or testing for all large businesses shot down, vaccine producers face an uncertain future. While the USSC did grant approval to another mandate, one requiring vaccines for healthcare workers at federally funded facilities, it affects a significantl
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
| Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.
by Team Stockjumpers